HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots names Japanese distributor for Clearasil

This article was originally published in The Rose Sheet

Executive Summary

Boots Healthcare International appoints Chuo Bussan International as distributor for Clearasil in Japan effective Dec. 3, UK firm announces. Acquisition of Clearasil provides BHI with first access to Japanese and U.S. markets, Boots adds. BHI expects to expand Clearasil distribution in 130 countries where Boots products are available. Product line likely will be expanded in fiscal 2002 to address a greater range of skin conditions, such as psoriasis, firm says. Boots recently named Novartis as Clearasil distributor in the U.S. and Canada; Boots purchased the brand from Procter & Gamble for $340 mil. last year (1"The Rose Sheet" May 21, In Brief and2 "The Rose Sheet" Oct. 23, 2000, p. 3)...

You may also be interested in...



Boots Healthcare Gains Access To U.S. Market Through Clearasil Buy

Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

UsernamePublicRestriction

Register

RS009823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel